𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Targeting cytotoxic T lymphocytes for cancer immunotherapy

✍ Scribed by Maher, J; Davies, E T


Book ID
109998189
Publisher
Nature Publishing Group
Year
2004
Tongue
English
Weight
157 KB
Volume
91
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Adoptive immunotherapy for advanced canc
✍ Soda, Hiroaki; Koda, Keiji; Yasutomi, Jun; Oda, Kenji; Takiguchi, Nobuhiro; Sait πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 219 KB πŸ‘ 2 views

## Background and Objectives: We evaluated the clinical efficacy of adoptive immunotherapy using in vitro activated cytotoxic T lymphocytes (CTL) in the treatment of patients with advanced cancer. Methods: CTL were induced with the mixed lymphocyte and tumor cell culture method, in which lymphocyte

Targeting cytotoxic T cells to antigen-s
✍ Hans-Georg Rammensee; Michael H. Julius; David Nemazee; Jean Langhorne; Rinus La πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 English βš– 368 KB

## Targeting cytotoxic T cells to antigen-specific B lymphocytes A recent development in immunomanipulation involves the targeting of cytotoxic T lymphocytes (CTL) to cell-bound antigens using bispecific antibodies. These antibodies have been engineered such that specificity is directed against th

Detection of peptide-specific cytotoxic
✍ Nobuaki Suzuki; Yoshiaki Maeda; Shoko Tanaka; Naoya Hida; Takashi Mine; Koutaro πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 French βš– 143 KB

## Abstract The prognosis of pancreatic cancer is extremely poor with a 5‐year survival of approximately 3%. Thus, the development of new treatment modalities, including a specific immunotherapy, is required. Our study investigated whether cytotoxic T‐lymphocyte (CTL) precursors reacting to peptide

Potential of human Ξ³Ξ΄ T lymphocytes for
✍ Dieter Kabelitz; Daniela Wesch; Elke Pitters; Margot ZΓΆller πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 French βš– 92 KB

## Abstract T lymphocytes are classified into 2 subsets based on their T‐cell receptor (TCR) expression. The vast majority of T cells expresses an Ξ±Ξ² TCR heterodimer. These Ξ±Ξ² T cells recognize antigenic peptides presented by MHC class I (for CD8^+^ T cells) or MHC class II molecules (for CD4^+^ T